ESMO FAMILY SITES
“Sarcomas represent paradigmatic tumor models for the development of targeted therapies in cancer. Building on a precise understanding of the molecular biology of 50% these tumors collected over the last decades, it is now possible to develop novel treatment targeting the initial molecular alterations driving these tumors. The aim of this meeting will be to understand these novel strategies for targeted agents in these tumors, with practical consequences on more frequent tumor types”.
Jean-Yves Blay
Program
CME accreditation
The program of this event will be:
- Accredited with 13 ESMO-MORA category 1 points
- Approved by the Accreditation Council for Oncology in Europe (ACOE) and designed for a maximum of 11 CME credits. ACOE accreditation has been endorsed by the Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS).
These credits are also recognized by the American Medical Association (AMA) as Physician’s Recognition. Award (AMA PRA Category 1 credits). - Accredited with 8 Italian CME points (crediti ECM)
BACK TO TOP
PRINT THIS PAGE